Statement From NIH and BARDA on the Novavax COVID-19 Vaccine
July 21, 2022
July 21, 2022
WASHINGTON, July 21 (TNSjou) -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
The Centers for Disease Control and Prevention (CDC) has recommended that Novavax's COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older. The Food and Drug Administration (FDA) previously authorized for emergency use the protein-based vaccine, known as NVX-CoV2373.
The Centers for Disease Control and Prevention (CDC) has recommended that Novavax's COVID-19 vaccine be used as another primary series option for adults in the United States ages 18 years and older. The Food and Drug Administration (FDA) previously authorized for emergency use the protein-based vaccine, known as NVX-CoV2373.